Neumora Therapeutics (NMRA) EBITDA (2022 - 2026)

Neumora Therapeutics' EBITDA history runs 5 years deep, the most recent figure standing at -$53.5 million for Q1 2026.

• In Q1 2026, EBITDA rose 21.45% year-over-year to -$53.5 million; the TTM figure through Mar 2026 stood at -$222.4 million (up 13.77% YoY), while the FY2025 annual figure was -$237.0 million, up 2.73% from the prior year.
• EBITDA was -$53.5 million for Q1 2026 at Neumora Therapeutics, up from -$59.5 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of -$27.8 million in Q4 2022 to a low of -$108.5 million in Q4 2023.
• Historically, EBITDA has averaged -$55.1 million across 5 years, with a median of -$53.8 million in 2024.
• The sharpest annual moves came in 2023 and 2024: EBITDA tumbled 290.75% in 2023, then jumped 45.75% in 2024.
• A 5-year view of EBITDA shows it stood at -$27.8 million in 2022, then sank by 290.75% to -$108.5 million in 2023, then surged by 45.75% to -$58.9 million in 2024, then retreated by 1.01% to -$59.5 million in 2025, then gained by 10.09% to -$53.5 million in 2026.
• The last three EBITDA figures came in at -$53.5 million (Q1 2026), -$59.5 million (Q4 2025), and -$56.7 million (Q3 2025), per Business Quant data.